Patents Assigned to SYNDAX PHARMACEUTICALS, INC.
  • Inhibitors of the menin-MLL interaction
    Patent number: 11919901
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: March 5, 2024
    Assignees: Syndax Pharmaceuticals, Inc., Vitae Pharmaceuticals, LLC
    Inventors: Gerard M. McGeehan, William H. Miller, Nicholas Paul Camp, Salvacion Cacatian, Santosh S. Kulkarni, Swapan Kumar Samanta, Virsinha Venkat Reddy
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20230061048
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Application
    Filed: March 29, 2022
    Publication date: March 2, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventor: Peter ORDENTLICH
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20230022573
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: April 8, 2022
    Publication date: January 26, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • Selection of patients for combination therapy
    Patent number: 11397184
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 26, 2022
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventor: Peter Ordentlich
  • Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
    Patent number: 11324822
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 10, 2022
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Robert Goodenow, Peter Ordentlich
  • Methods for the treatment of breast cancer
    Patent number: 10226472
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 12, 2019
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Robert Goodenow, Peter Ordentlich
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20180252721
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Application
    Filed: September 2, 2016
    Publication date: September 6, 2018
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventor: Peter Ordentlich
  • METHODS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20140378420
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 25, 2014
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Robert Goodenow, Peter Ordentlich
  • ADMINISTRATION OF AN INHIBITOR OF HDAC
    Publication number: 20130303575
    Abstract: Methods of treating patients with SNDX-275 are provided.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 14, 2013
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Konrad BURKE, Peter ORDENTLICH, Robert S. Goodenow
  • METHODS FOR THE TREATMENT OF LUNG CANCER
    Publication number: 20130150386
    Abstract: Described herein are methods for the treatment of lung cancer in a subject. In particular, methods are provided for the treatment of resistant lung cancer with a combination of entinostat and an EGFR inhibitor.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 13, 2013
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventor: Syndax Pharmaceuticals, Inc.
  • Administration of an Inhibitor of HDAC
    Publication number: 20100305167
    Abstract: Methods of treating patients with SNDX-275 are provided.
    Type: Application
    Filed: November 19, 2008
    Publication date: December 2, 2010
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Konrad Burk, Peter Ordentlich, Robert Goodenow
  • Novel Compounds and Methods of Using Them
    Publication number: 20100298270
    Abstract: Described herein are novel HDAC modulators, formulations containing them and methods of using them. In some embodiments, the HDAC modulators possess specific stereo chemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.
    Type: Application
    Filed: July 23, 2008
    Publication date: November 25, 2010
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: John F.W. Keana, Peter Ordentlich, Robert Goodenow
  • Novel Compounds and Methods of Using Them
    Publication number: 20100267779
    Abstract: Described herein are novel HDAC inhibitors, formulations containing them and methods of using them. In some embodiments, the HDAC inhibitors possess specific stereochemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.
    Type: Application
    Filed: July 23, 2008
    Publication date: October 21, 2010
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: John F.W. Keana, Peter Ordentlich, Robert Goodenow
  • Administration of an Inhibitor of HDAC and an mTOR Inhibitor
    Publication number: 20090149511
    Abstract: Methods of treating patients with an HDAC inhibitor and an mTOR inhibitor are provided.
    Type: Application
    Filed: October 29, 2008
    Publication date: June 11, 2009
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Konrad Burk, Peter Ordentlich, Robert Goodenow
  • COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20080242648
    Abstract: The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ER?+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
    Type: Application
    Filed: November 9, 2007
    Publication date: October 2, 2008
    Applicant: Syndax Pharmaceuticals, Inc., a California Corporation
    Inventors: Peter Ordentlich, Joanna Horobin, Martha Jo Whitehouse, Miranda Rees